FemBloc Permanent Contraceptive System

Description: A degradable biopolymer is sent through a catheter-based delivery system placed in the uterus to permanently block the fallopian tubes after several weeks.

Product Details

User: Female

Hormonal: No

Delivery Method: Intrauterine

Duration Type: Permanent

Duration: Permanent

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Femasys Inc

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase I

Active Development: Yes

Status Details:
  • IDE approval granted by FDA in 2016 for U.S. prospective, multi-center clinical trial of FemBloc that began in 2017.

Additional Information

References:
  • Femasys website: http://www.femasys.com/

  • ClinicalTrials.gov Identified NCT03067272

  • ClinicalTrials.gov Identified NCT03433911

Vertical Tabs

Print